Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue by Bouwens van der Vlis, T.A.M. et al.
Journal of Neuroimmunology 278 (2015) 271–276
Contents lists available at ScienceDirect
Journal of Neuroimmunology
j ourna l homepage: www.e lsev ie r .com/ locate / jneuro imComplement activation in Glioblastoma Multiforme pathophysiology:
Evidence from serum levels and presence of complement activation
products in tumor tissueT.A.M. Bouwens a, L.A. Trouw b, R. Veerhuis c, C.M.F. Dirven a, M.L.M. Lamfers a, H. Al-Khawaja a,⁎
a Erasmus University Medical Center, Brain Tumor Center, Department of Neurosurgery, Dr. Molewaterplein 50, 3015 GE Rotterdam, Netherlands
b Leiden University Medical Center, Department of Rheumatology, PO Box 9600, 2300 RC Leiden, Netherlands
c Vrije University Medical Center, Departments of Clinical Chemistry and Psychiatry, PO Box 7057, 1007 MB Amsterdam, Netherlands⁎ Corresponding author at: Erasmus University M
Neurosurgery, Room Hs 116, Netherlands. Tel.: +31 6 36
E-mail address: h.alkhawaja@erasmusmc.nl (H. Al-Kh
http://dx.doi.org/10.1016/j.jneuroim.2014.11.016
0165-5728/© 2014 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 29 September 2014
Received in revised form 13 November 2014
Accepted 14 November 2014
Keywords:
Glial tumor
Complement system
Mannose Binding Lectin (MBL)
C1q
Factor B
Glioblastoma MultiformeInﬂammation plays a key role in the pathophysiology of Glioblastoma Multiforme (GBM). Here we focus on the
contribution of the so far largely ignored complement system.
ELISA and immunohistochemistry were combined to assess levels and localization of critical components of the
initiation- and effector pathways of the complement cascade in sera and tumor tissue from GBM patients and
matched controls.
Serum levels of factor-B were decreased in GBM patients whereas C1q levels were increased. C1q and factor-B
deposited in the tumor tissue. Deposition of C3 and C5b-9 suggests local complement activation. MBL deﬁciency,
based on serum levels, was signiﬁcantly less frequent among GBM patients compared to controls (14% vs. 33%).
Therefore low levels of MBL may protect against the initiation/progression of GBM.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Gliomas are the most common type of primary brain tumors in
adults. GlioblastomaMultiforme (GBM) accounts for over 51% of all gli-
omas, and newly diagnosedGBMs show anoverall survival of 17–30% at
one year, and only 3–5% at two years (Adamson et al., 2009). Despite the
increasing extent of surgical resections using state-of-the art preopera-
tive, intraoperative neuroimaging and monitoring techniques and
advances in radiotherapy and chemotherapy, the prognosis for GBMpa-
tients remains dismal (Li et al., 2009). The etiology of GBM still remains
largely unknown but probably involves genetic, immunologic, hormon-
al as well as environmental factors (Kanu et al., 2009).
Several studies of human cancers have established that chronic and
insidious inﬂammation promotes the process of carcinogenesis and ex-
acerbates the growth of existing tumors (Balkwill andMantovani, 2001;
Wiemann and Starnes, 1994). Components of the adaptive immune
system have been identiﬁed in GBM patients, indicating involvement
of immune activation in the pathology of GBM. Surprisingly, very little
is known about the contribution of innate immunity in GBM patients
(Bach et al., 2009).edical Center, Department of
176830.
awaja).
. This is an open access article underThe human complement system is a major contributor to both
adaptive and innate immunity, and forms a functional bridge
between the innate and adaptive immune response (Ricklin et al.,
2010). The complement system comprises around thirty ﬂuid
phase as well as membrane-associated proteins. Apart from being
the ﬁrst line of defense against microbial invasion it is also thought
to additionally take part in a range of diverse processes including
synapse maturation and phagocytosis of cellular debris.
Three pathways of complement activation have been recognized;
the lectin pathway (LP), the classical pathway (CP) and the alternative
pathway (AP). These pathways are activated via their recognition mol-
ecules, C1q, Mannose Binding Lectin and C3-H2O. Genetic variants, both
common Single Nucleotide Polymorphisms and mutations have been
identiﬁed in the complement genes. Some of the variants in C1q and
MBL can have interesting consequences. Genetic variants in both C1q
and MBL, can increase the susceptibility to speciﬁc infections (Turner,
2003). Although being very rare, mutations in either one of the three
genes encoding for C1q is almost always accompanied by the pres-
ence of Systemic Lupus Erythematosus. Certain SNPs can result in
complete MBL deﬁciency with a frequency up to 40% in healthy Cau-
casian adults and are associated with cardiovascular disease
(Minchinton et al., 2002; Mead et al., 1997; Madsen et al., 1994;
Skattum et al., 2011). Increased serum levels and activity are seen
for MBL in colorectal cancer and newly diagnosed acute myeloid
leukemia patients (Ytting et al., 2004).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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the fundamental requirements of the malignant cell, as it was shown
to sustain proliferative signaling, angiogenesis, resistance to apoptosis,
and also to modulate anti-tumor immunity and activate invasion and
migration (Rutkowski et al., 2010; Hanahan and Weinberg, 2011).
Therefore, the activated complement cascade is thought to exert great
inﬂuence on tumor progression and survival of tumor patients. Conse-
quently, high levels of complement activation proteins may be beneﬁ-
cial for the tumor (Markiewski et al., 2008; Markiewski and Lambris,
2009a,b). In sharp contrast, several studies have reported on the possi-
bility to eradicate tumors by increasing complement activation on
tumor cells by i.e. inhibiting endogenous complement inhibitors
through application of monoclonal antibodies (Beurskens et al., 2012;
Teeling et al., 2004).
Genetic status and consequently serum levels of key proteins of the
activation pathways have, as illustrated above, successfully been related
to a variety of diseases. However, the precise involvement of the com-
plement cascade on glial tumor pathophysiology remains, yet, unex-
plained. In the present study, the degree to which complement is
activated and which activation pathways of complement activation
are involved in GBM was studied in different stages of glial tumor
progression. Deposition of C1q and C3 was observed in tumor tissue,
suggesting a role for complement in GBM pathogenesis. Remarkably,
a lower frequency of innate MBL deﬁciency in GBM patients was ob-
served in this study, suggesting a protective effect on tumor initiation/
progression.
2. Material and methods
2.1. Patient samples
Tissue and serum samples were obtained during elective debulking
surgery of susceptible primary glial tumor patients at the ErasmusMed-
ical Centre, Rotterdam, The Netherlands. Tumor tissue samples were
immediately snap-frozen in liquid N2 and together with sera stored at
−80 °C until further analysis. Sample collection and handling was per-
formedwith informed consent frompatients as approved by the institu-
tional review board of the Erasmus Medical Center, Rotterdam, The
Netherlands.
Of the 131 patients who were operated with suspected intracranial
glial tumor disease, histopathological analysis conﬁrmed 113 glial tu-
mors of which 71 patients with WHO grade IV Glioblastoma
Multiforme, 22 WHO grade III, and 20 WHO grade II. The grade III and
grade II glial tumors comprised of (anaplastic) oligodendroglioma, (an-
aplastic) astrocytoma and (anaplastic) oligoastrocytoma. All were in-
cluded for further analysis of preoperative serum concentrations of
C1q, MBL and factor B. See Table 1 for patient demographics.
2.2. Immunohistochemical- and immunoﬂuorescence-stainings
Immunohistochemistry was performed using cryopreserved−80 °C
serial tissue sections (6 μm). Tissue sections were ﬁxedwith cold acetone
(10min) and rehydrated using phosphate-buffered saline (PBS). Sections
were then incubated with peroxidase blocking reagent (DAKO; Glostrup,
Denmark) and subsequently with 1:10 normal Goat serum (Sigma-Al-
drich, St. Louis, USA). After rinsing with PBS, sections were incubatedTable 1
Patient demographics. * indicates signiﬁcant difference (p b 0001; Student's t-test)
compared to mean age healthy controls.
Patient demographics
Healthy controls Glial tumor GBM WHO III WHO II
N 209 113 71 22 20
Mean age 44 52 58* 42 43
Male/female 103/106 61/52 38/33 14/8 9/111 h at RT with polyclonal antibodies diluted in PBS containing 1% BSA
(PBS–BSA) speciﬁcally staining human MBL (Mannose Binding Lectin;
1:250 DAKO) C1q (1:1000 DAKO), factor B (Santa Cruz Biotechnology,
Santa Cruz, USA), C3c (1:500 DAKO) and C5b-9 complex (1:200 Santa
Cruz Biotechnology, Santa Cruz, USA) followed bywashingwith PBS. Per-
oxidase conjugated anti rabbit/mouseHRP (EnvisionKit, DAKO)was used
as a secondary antibody for all tissue sections. Sections were developed
with diaminobenzidinetetrahydrochloride (DAB) and counterstained
withMayer's hematoxylin to allowmorphological analysis. The speciﬁcity
of the antibody stainingwas conﬁrmed by omitting the primary antibody.
For immunoﬂuorescence staining the acetone ﬁxated sections were
incubated with PBS–BSA for 30 min and washed in PBS. Primary anti-
body incubation (1 h) was followed by washing and incubation
(30 min) of the tissue sections with anti-mouse Alexa 488 IgG
(Invitrogen, USA; 1:250) or anti-rabbit Alexa 568 IgG (Invitrogen, Carls-
bad, USA; 1:500) and nuclei were stained with DAPI (Vector Laborato-
ries, Burlingame USA). All incubation steps were performed using
PBS–BSA as a buffer at room temperature.
2.3. ELISA for MBL and C1q
Enzyme-linked immunosorbent assays (ELISA) for the detection of
human MBL and C1q were developed and used as previously described
(Castellano et al., 2004; Roos et al., 2001; Worthley et al., 2006). The
Sandwich ELISA for factor B was performed by coating goat anti
human Factor B (Quidel, San Diego, USA) overnight at room tempera-
ture. Following blocking with PBS–BSA for 1 h at 37 °C plates were
washed and a standard of Normal Human Serum (NHS) or the patient
samples diluted in PBS–BSA–0.05% Tween were incubated for 1 h at
37 °C. Following additional washing the plates were incubated with
mouse anti-factor B (Quidel) followed by goat anti-mouse IgG-HRP
(DAKO) and assay development using the substrate ABTS.
2.4. Total protein analysis and correction
Total protein was measured for each serum protein sample of both
glial tumor patients and healthy controls in quadruple using a BCA
assay (Pierce, Rockford, USA). To correct for small total protein discrep-
ancies between healthy controls and glial tumor patients, protein levels
of C1q, MBL and factor B were divided by the corresponding total pro-
tein concentration for each sample and normalized to the mean protein
content of sera of the healthy controls.
2.5. Survival analysis
Survival curves from date of operation were plotted for the 25th vs.
75th percentile of the corrected factor B and C1q serum concentrations.
For MBL, the survival curves were drawn for MBL deﬁcient vs. MBL suf-
ﬁcient patients. In this analysis only GBM patients were taken into ac-
count who did not meet exclusion criteria. Exclusion criteria
comprised of post-operative death deﬁned as death b1month after sur-
gery, recurrent/secondary glioblastoma, and unnatural and unknown
cause of death. Of the initially included 71 patients 52patients remained
for survival analysis.
2.6. Statistical analysis
Differences between Kaplan–Meier survival curves were calculated
by the log-rank (Mantel–Cox) test. Protein levels of the serum samples
from separate WHO classiﬁcations were individually compared to the
Healthy controls by Student's t-test. MBL deﬁciency in glial tumor grad-
ing compared to healthy controlswas analyzed usingChi (Li et al., 2009)
test. All analyseswere performed using SPSS 17.0 (SPSS Inc., Chicago) or
Graphpad Prism 5.00 (Graphpad Inc.) software.
Fig. 1.Mean sera levels of C1q (A), factor B (B) andMBL (C) of glial tumor patients compared to age and sex matched controls. The *, **, and *** indicate signiﬁcance levels of p b 0.05, p b
0.01, and p b 0.0001. n.s., not signiﬁcant.
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3.1. Altered serum level of C1q, factor B and MBL in glial tumor patients
In order to evaluate quantitative differences in levels of the recogni-
tionmolecules of the three complement pathways (CP, AP, LP) between
glial tumor patients and healthy controls, we performed ELISA for C1q,
MBL and factor B on sera of patients and controls. We measured total
protein concentrations of the sera of patients and controls and observed
small differences. Therefore we corrected the measured levels of C1q,
MBL and factor B for total protein content in each sample.
The mean concentrations of C1q in glioma patients, 145 ± 4 μg/ml
(mean, SEM, N= 113), was signiﬁcantly increased as compared to con-
trols 121 ± 2 μg/ml (Mean, SEM, N = 208). For Factor B a signiﬁcantly
decreased concentration in patients was noted, 1556 ± 100 aU/ml, as
compared to the controls 1996 ± 85 aU/ml. Fig. 1A and B shows the
scatter plots of the corrected C1q and factor B concentrations in healthy
controls and glial tumor patients when divided into theWHO classiﬁca-
tion for gliomas.
Evaluation of the MBL serum levels in patients with glial tumor ver-
sus healthy controls revealed elevated MBL concentrations in the glial
tumor group 870 ± 75 ng/ml versus 404 ± 41 ng/ml, (p b 0.0001).
When divided into subgroups according to the WHO classiﬁcation for
gliomas, all groups showed a signiﬁcant increase in mean MBL
(Fig. 1c). The frequency of MBL deﬁciency, deﬁned as b100 ng/ml, in
our control group (33%), corresponds with the normal distribution in
the western population (Minchinton et al., 2002). The frequency of
MBL deﬁciency was strongly decreased in the GBM group versus the
control group (14% vs. 33%; p = 0.006), as shown in Table 2 and Fig. 1c.
3.2. Complement deposition in tumor tissue
The observed changes in C1q, factor B andMBL serum levels may re-
ﬂect the involvement of these proteins in the tumor process. Therefore
we performed immunohistochemistry on tumor tissue in order to iden-
tify the deposition of C1q, factor B and MBL at the protein level.
Interestingly, C1q was highly present in tumor tissue as shown in
Fig. 2, independent of CD45 positive leukocytic inﬁltration (Fig. 2c),
and suggesting deposition on tumor cells. Factor B and MBL were alsoTable 2
Frequency distribution of MBL deﬁciency in GBM patients (14%) compared to healthy
controls (33%). χ2 test, p = 0.002.
Frequency of MBL deﬁciency
MBL Total
Non-deﬁcient Deﬁcient
Control group 139 69 208
GBM patients 61 10 71
Total 200 79 279present in tumor tissue (Fig. 3), but show relatively lower staining in-
tensities as compared to C1q.
The three initiatingpathways of the complement systemconverge at
the level of proteolytic cleavage of C3 that, ultimately, may lead to full-
blown activation of the complement cascade and to the formation of the
C5b-9 complex. Consequently, the presence of C3 in tumor tissue is es-
sential for the continuation of the complement cascade. Fig. 4 shows the
diffuse staining pattern of C3, which is abundantly present in both ne-
crotic and non-necrotic areas of GBM tumor tissue. In addition, the
C5b-9 complex was detected on individual cells in GBM tumor tissue
(Fig. 5), which indicates that complement activation up to the C5b-9
complex locally has taken place.
3.3. Complement levels are not overtly associated with patient survival
In order to identify thepossible inﬂuence of preoperativeMBL, C1q or
factor B serum concentrations on GBM survival, survival curves were
plotted for subdivisions of these groups (C1q, factor B 25th and 75th per-
centiles,MBL sufﬁcient anddeﬁcient). KaplanMeier curves did not show
signiﬁcant survival difference in the three groups, as depicted in Fig. 6.
4. Discussion
Glioblastoma Multiforme is a primary brain tumor, which shows
an aggressive clinical course despite debulking surgery and chemo-
radiation treatment. This malignant process is characterized by its inﬁl-
trative nature, hyper vascularization, presence of necrosis and impair-
ment of the blood–brain barrier. These characteristics could in theory
be aided or facilitated by the immunological response to the tumor pro-
cess. Components of the adaptive immune system have been identiﬁed
in gliobastomapatientswhereas only little is known about the contribu-
tion of innate immunity.
Under healthy conditions, the blood–brain barrier restricts the inﬂux
of blood borne cells and proteins into the brain parenchyma. Immune
surveillance and differentiation between “self” and “non-self” in the
brain are under normal conditions provided by resident cells, including
microglia and astrocytes. These glial cells, and also neurons can locally
produce complement factors and regulatory proteins (Veerhuis et al.,
1996, 1999). The complement cascade is mainly responsible for the
clearance of micro-organisms and senescent or ‘altered’ cells in the
healthy brain and during embryonal development in synapse pruning
and development of neural networks. In disease conditions, comple-
ment activation is evident in acute brain injury (infection, trauma,
stroke) and also in neurodegenerative diseases (including Alzheimer's
disease) associated with chronic inﬂammatory processes.(Veerhuis
et al., 2011) In this study we investigated the involvement of the three
complement cascade initiating pathways and its consequences in
terms of complement pathway continuation in GBM by determining
preoperative serum levels and tissue localizations of C1q, MBL, factor
B, as well as of C3 and C5b-9.
Fig. 2. Immunohistochemical staining of GBM slides for C1q using a standard IHC protocol: primary antibody was diluted 1000×, slides were developed using DAB. Pictures taken at 16×
(A) and 40× (B) magniﬁcations. C: Immunoﬂuorescence staining of GBM tissue for C1q (1:1000 red) using a double staining protocol together with CD45 (1:250 green). Pictures were
taken at 16× magniﬁcation.
Fig. 3. Immunoﬂuorescence staining of GBM tissue for factor B and MBL using a double-staining protocol together with astrocyte marker Glial ﬁbrillary acidic protein (GFAP). A: MBL
(1:200 red) GFAP (1:250 green), 16× magniﬁcation. B: Factor B (1:200 red) GFAP (1:250 green), 16× magniﬁcation.
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gene are associatedwith decreased concentrations. Very low concentra-
tions of functional Mannose Binding-Lectin (b100 ng/ml) are consid-
ered to be a reﬂection of homozygous mutations in the MBL2 gene. InFig. 4. Immunohistochemical staining of GBM slides for C3c using a standard IHC protocol: prim
(A) and 40× (B) magniﬁcations. C: Immunoﬂuorescence staining of GBM tissue for C3c (1:100
Fig. 5. Immunohistochemical staining of GBM slides for the C5b-9 complex using a standard IHC
taken at 16× (A) and 40× (B) magniﬁcations. C: Immunoﬂuorescence staining of GBM tissue fgeneral accordance with large epidemiologic studies, our age and
gender matched control subjects show a frequency of MBL deﬁciency
of 33%. Interestingly, we found MBL deﬁciency in only 14% of the
glioblastoma subjects (Table 2), which could suggest a possible cancerary antibody was diluted 1000×, slides were developed using DAB. Pictures taken at 16×
0 green). Picture taken at 16× magniﬁcation.
protocol: primary antibody was diluted 250×, slides were developed using DAB. Pictures
or C5b-9 complex (1:250 red). Picture taken at 66× magniﬁcation.
Fig. 6.KaplanMeier curves. C1q 25th versus 75th percentile did not signiﬁcantly differ for survival (p=0384) as 25th and 75th percentiles of factor B (p=0.661) andMBL deﬁcient versus
sufﬁcient (p = 0.188).
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disposes to stomach cancer (Baccarelli et al., 2006). MBL serum concen-
tration was found to be increased in glioblastoma patients which either
could be a reﬂection primarily of the tumor process, or a response to
surgery or inﬂammation elsewhere., This increase has also been ob-
served for colorectal and pancreatic cancer patients (Ytting et al.,
2004; Rong et al., 2010). The exact implication of the presence of MBL
in cancer biology remains yet to be understood. MBL deﬁciency did
not signiﬁcantly correlate with GBM survival, when MBL deﬁcient and
MBL sufﬁcient subjects were compared, suggesting that MBL deﬁciency
does not inﬂuence tumor progression, but tumor initiation. Future in-
vivo research will assess the possible protective role of MBL deﬁciency
and the impact of the increase of MBL serum concentration.
Further focusing on the classical pathway, the initiating component of
this pathway C1q, circulates in a complex with C1r and C1s to form C1.
We observed an increase in C1q serum concentration in comparison to
our healthy controls, which can be attributed to reactive upregulation
by the tumor process as observed in infectious diseases as active tuber-
culosis and bacterial meningitis (Cai et al., 2014; Mook-Kanamori et al.,
2014).
Immunohistochemical staining shows the abundant presence of C1q
in the vicinity of both malignant cells and necrotic debris in sections of
GBM tissue. The presence of necrotic tissue, one of the main pathologi-
cal characteristics and diagnostic features of GBM, could contribute to
the C1q consumption (Jensen, 2009). C1q binding onnecrotic or late ap-
optotic tumor cells induces complement activation and therefore depo-
sition of speciﬁc complement components, which can act as opsonins
and facilitate phagocytosis (Trouw et al., 2008; Gullstrand et al., 2009;
Nauta et al., 2002;Martin et al., 2012). The presence of C1q in tumor tis-
sue could either be beneﬁcial or detrimental regarding tumor growth.
C1q is able to induce apoptosis in malignant cells through activation of
the tumor suppressor WOX1 as is shown for prostate cancer (Hong
et al., 2009).
Preoperative low C1q concentration (25th percentile) was not sig-
niﬁcantly related to survival as compared to the 75th percentile. C1qde-
position, either indirect or direct, can be attended with deposition of
factor H, a soluble AP regulation protein (Yin et al., 2007; Kang et al.,
2012). Factor H blocks AP C3-convertase and, as cofactor for factor I, it
potentiates degradation C3b and C4b. However, a positive regulator
of the alternative pathway, properdin, is also known to bind to late ap-
optotic or necrotic cells (Xu et al., 2008). In this perspective, we also ob-
served factor B deposition in tumor slices. This deposition of factor B
could contribute to the degradation of the ECM and therefore promote
tumor invasion and migration (Andrades et al., 1996). However,
tumor bearing factor B deﬁcient mice did not show different tumor
growth compared to wild-type controls (Markiewski et al., 2008). Nev-
ertheless, our data suggests that factor B is actively consumed by the
glial tumor process, which might imply a further activation of the com-
plement cascade through the formation of AP C3-convertase. The three
initiating pathways converge at the level of proteolytic cleavage of C3
into C3a and C3b after the formation of C3 convertases. Therefore it is
important to investigate the presence of C3 in order to determinewhether the continuation of the complement cascade is facilitated.
Our GBM sections showed the profound presence of C3 deposition
compared to sections of post-mortem healthy brain tissue. This de-
posited C3 initiated further complement activation as evidenced
by deposition of the C5b-9 complex.
In conclusion, we show that serum concentration of critical compo-
nents of the classical, lectin and alternative complement pathways are
signiﬁcantly altered in glial tumor patients, suggesting the involvement
of the innate immune system in glial tumor pathology. In addition, the
presence of C3 deposition and more speciﬁcally the deposition of the
C5b-9 complex, suggests that glioblastoma tumor localized comple-
ment activation. Serum concentrations of these three critical proteins
of initiation pathways of the complement system were not correlated
with survival. However, the frequency of MBL deﬁciency was strongly
reduced in GBM patients, which may implicate a protective effect
against developing the disease. Future in-vivo research will have to re-
veal the exact inﬂuence of complement involvement on glial tumor pro-
gression as well as the possible consequence of MBL deﬁciency.Acknowledgements
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